HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

benzmetanide (H 25)

Also Known As:

H 25; H-25; 3-benzylamino-4-phenoxy-5-sulfamoylbenzoic acid

Networked: 49 relevant articles (4 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133

Experts

1.	Chen, Bin: 2 articles (11/2012 - 02/2012)
2.	Hu, Wei: 2 articles (11/2012 - 02/2012)
3.	Alomari, Safwan: 1 article (01/2022)
4.	Bydon, Ali: 1 article (01/2022)
5.	Judy, Brendan: 1 article (01/2022)
6.	Lo, Sheng-Fu L: 1 article (01/2022)
7.	Sciubba, Daniel M: 1 article (01/2022)
8.	Theodore, Nicholas: 1 article (01/2022)
9.	Weingart, Jon: 1 article (01/2022)
10.	Witham, Timothy: 1 article (01/2022)

Related Diseases

1.	Heart Failure 01/01/2005 - "The lowest quartile was compared with the rest of the studied population (VE: group with high (H)>15.6 microM>group with low (L), BC: H>0.07 microM>L, VC: H>25 microM>L) in the following parameters: extent of myocardial damage (area under the curves of troponin I, CK-MB during 48 h), arrhythmia and congestive heart failure occurrence, size of ejection fraction, positivity of ventricular late potentials. " 04/01/2011 - "The title compound, eprosartan mesylate {systematic name: 2-butyl-1-(4-carb-oxy-benz-yl)-5-[(E)-2-carb-oxy-3-(thio-phen-2-yl)prop-1-en-yl]-1H-imidazol-3-ium methane-sulfonate}, C(23)H(25)N(2)O(4)S(+)·CH(3)O(3)S(-), one of the angiotensin II-receptor antagonists, is effective in regulating hypertension, induced or exacerbated by angiotensin II, and in the treatment of congestive heart failure, renal failure and glaucoma. "
2.	Renal Insufficiency (Renal Failure) 04/01/2011 - "The title compound, eprosartan mesylate {systematic name: 2-butyl-1-(4-carb-oxy-benz-yl)-5-[(E)-2-carb-oxy-3-(thio-phen-2-yl)prop-1-en-yl]-1H-imidazol-3-ium methane-sulfonate}, C(23)H(25)N(2)O(4)S(+)·CH(3)O(3)S(-), one of the angiotensin II-receptor antagonists, is effective in regulating hypertension, induced or exacerbated by angiotensin II, and in the treatment of congestive heart failure, renal failure and glaucoma. "
3.	Weight Loss (Weight Reduction) 12/01/2014 - "Alternate day fasting (ADF; 24-h feeding/24-h 25% energy intake at lunchtime), is effective for weight loss, but diet tolerability is questionable. "
4.	Infections 10/01/1993 - "2 weeks after infection with Mycobacterium tuberculosis H37Rv, groups of mice were treated with rifampicin (R) 15 mg/kg, isoniazid (H) 25 mg/kg, pyrazinamide (Z) 300 mg/kg, ethambutol (E) 100 mg/kg three times weekly (RHZE3); RH/ZE, an alternating regimen of RH on days 1, 3 and 5 of the week and ZE on days 2, 4 and 6, RZ/HE or RE/HZ. Spleen and lung bacillary counts at 7 and 12 weeks indicated large differences in the efficacy of the regimens: RZ/HE > RE/HZ > RHZE3 > RH/ZE. "
5.	Hypertension (High Blood Pressure) 04/01/2011 - "The title compound, eprosartan mesylate {systematic name: 2-butyl-1-(4-carb-oxy-benz-yl)-5-[(E)-2-carb-oxy-3-(thio-phen-2-yl)prop-1-en-yl]-1H-imidazol-3-ium methane-sulfonate}, C(23)H(25)N(2)O(4)S(+)·CH(3)O(3)S(-), one of the angiotensin II-receptor antagonists, is effective in regulating hypertension, induced or exacerbated by angiotensin II, and in the treatment of congestive heart failure, renal failure and glaucoma. "

Related Drugs and Biologics

1.	Angiotensin Receptor Antagonists
2.	Rifampin (Rifampicin)
3.	Pyrazinamide
4.	Mesylates (Mesylate)
5.	Isoniazid (Ftivazide)
6.	Ethambutol (Myambutol)
7.	Angiotensin II
8.	Tolvaptan
9.	Z 300
10.	eprosartan (Teveten)

Related Therapies and Procedures

1.	Transjugular Intrahepatic Portasystemic Shunt
2.	Renal Replacement Therapy (Therapies, Renal Replacement)
3.	Tourniquets
4.	Thyroidectomy
5.	Therapeutics